Publications by authors named "D D Loeb"
The Golgi apparatus is a critical organelle responsible for intracellular trafficking and signaling, orchestrating essential processes such as protein and lipid sorting . Dysregulation of its function has been implicated in various pathologies, including obesity, diabetes, and cancer, highlighting its importance as a potential therapeutic target. Despite this, the development of tools to selectively target the Golgi in specific cell types remain a significant unmet challenge in imaging and drug discovery.
View Article and Find Full Text PDFContext: Guidelines for use of injectable estradiol esters (valerate [EV] and cypionate [EC]) among transgender and gender diverse (TGD) individuals designated male at birth vary considerably, with many providers noting supraphysiologic serum estradiol concentrations based on current dosing recommendations.
Objectives: 1. Determine dose of injectable estradiol (subcutaneous [SC] and intramuscular [IM]) needed to reach guideline-recommended estradiol concentrations for TGD adults using EC/EV.
Osteosarcoma (OS) is the most common primary malignant bone tumor in childhood. Patients who present with metastatic disease at diagnosis or relapse have a very poor prognosis, and this has not changed over the past four decades. The Wnt signaling pathway plays a role in regulating osteogenesis and is implicated in OS pathogenesis.
View Article and Find Full Text PDFOsteosarcoma (OS) is the most common primary malignant bone tumor in childhood. Patients who present with metastatic disease at diagnosis or relapse have a very poor prognosis, and this has not changed over the past four decades. The Wnt signaling pathway plays a role in regulating osteogenesis and is implicated in OS pathogenesis.
View Article and Find Full Text PDFArticle Synopsis
- - A Phase II trial was conducted to evaluate the combination of gemcitabine and nab-paclitaxel for treating recurrent osteosarcoma in patients aged 12-30, with an emphasis on assessing progression-free survival and identifying potential biomarkers.
- - Eighteen patients participated, showing a 28% progression-free survival rate after four months, with some experiencing partial responses but facing dose reductions and toxicities.
- - The study concluded that the gemcitabine and nab-paclitaxel combination has comparable effectiveness and toxicity to previous treatments with gemcitabine and docetaxel, while highlighting the potential for using circulating tumor cells and circulating tumor DNA as response biomarkers in future research.